Lineage Cell Therapeutics, Inc. Gains 24.53%
Mon, Apr 05, 2021 at 05:30 PM
Lineage Cell Therapeutics, Inc. (BTX:NYSEMKT) rocketted at $4.67, representing a gain of 24.5%. On Thu, Apr 01, 2021, BTX:NYSEMKT hit a New 2-Week Intraday Low of $3.59. The stock appeared on our News Catalysts scanner on Thu, Apr 01, 2021 at 09:59 AM in the 'MERGER' category. From Thu, Mar 18, 2021, the stock recorded 30.00% Up Days and 27.27% Green Days
The stock spiked on Tue, Mar 16, 2021 at $10.28 with a volume of 3M+.
About Lineage Cell Therapeutics, Inc. (BTX:NYSEMKT)
BioTime Inc focuses regenerative medicine technologies in ophthalmology, soft tissue reconstruction, and the local delivery of cells and therapeutics.
Top 10 Gainers:
- Chembio Diagnostics, Inc. (CEMI:NASDAQ), 60.23%
- Xcel Brands, Inc. (XELB:NASDAQ), 51.27%
- DMYD (DMYD:NYSE), 40.76%
- Sequential Brands Group, Inc. (SQBG:NASDAQ), 32.4%
- VVOS (VVOS:NASDAQ), 27.21%
- Moxian, Inc. (MOXC:NASDAQ), 26.16%
- U.S. Global Investors, Inc. (GROW:NASDAQ), 25.14%
- Performant Financial Corporation (PFMT:NASDAQ), 25%
- Lineage Cell Therapeutics, Inc. (BTX:NYSEMKT), 24.53%
- Regional Health Properties, Inc. (RHE:NYSEMKT), 24.18%